3 months and 1 year of oral anticoagulant therapy were equivalent for idiopathic proximal deep venous thrombosis

January 2002
ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p11
Academic Journal
Presents an abstract of the study 'Three Months Versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis,' by G. Agnelli, P. Prandoni, M. G. Santamaria, et. al., and the Warfarin Optimal Duration Italian Trial Investigators, published on the July 19, 2001 issue of the 'New England Journal of Medicine.' Comment on the study.


Related Articles

  • Malignancies increased risk for non-leg DVT.  // Hem/Onc Today;6/25/2014, Vol. 15 Issue 12, p42 

    The article discusses the results of a nested prospective cohort study which appeared in an article by F. Lamontagne in a 2014 issue of the "Journal of the American Medical Association (JAMA) Internal Medicine," showing the low adherence with guidelines on a suggested course of therapeutic...

  • ticlopidine.  // Royal Society of Medicine: Medicines;2002, p534 

    This article presents information on ticlopidine, an antiplatelet drug which is used to prevent thrombosis, but does not have an anticoagulant action. It works by stopping platelets sticking to one another or to the walls of blood vessels. It is used to reduce complications in patients with...

  • tirofiban.  // Royal Society of Medicine: Medicines;2002, p536 

    This article provides information on tirofiban which can be used to prevent thrombosis or blood-clot formation. The antithrombic drug works by stopping platelets sticking to one another or to the walls of blood vessels. It can be used together with heparin and aspirin to prevent thrombosis in...

  • Long-term and short-term oral anticoagulation therapies were equivalent for venous thromboembolism. Kearon, Clive // ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p10 

    Presents an abstract of the study 'Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis,' by L. Pinede, J. Ninet, P. Duhaut, et...

  • A MOUSE MINUS CLOTTING FACTOR GENE. Kingman, Sharon // BioWorld Today;2/11/2014, Vol. 25 Issue 28, p9 

    The article focuses on the anticoagulation therapy experiments using the antibody 3F7 developed in 2005 by Swedish, Australian and German researchers. The study showed that mice which were manipulated genetically to block the clotting factor XII were protected from the development of thrombosis....

  • Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Campbell, I.A.; Bentley, D.P.; Prescott, R.J.; Routledge, P.A.; Shetty, H.G.M.; Williamson, I.J. // BMJ: British Medical Journal (International Edition);3/31/2007, Vol. 334 Issue 7295, p674 

    ABSTRACT Objective To determine the optimum duration of oral anticoagulant therapy after an episode of deep vein thrombosis or pulmonary embolism, or both. Design Multicentre, prospective, randomised study with follow-up for one year. Setting 46 hospitals in United Kingdom. Participants Patients...

  • Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. Agnelli, Giancarlo; Prandoni, Paolo; Santamaria, Maria Gabriella; Bagatella, Paola; Iorio, Alfonso; Bazzan, Mario; Moia, Marco; Guazzaloca, Giuliana; Bertoldi, Adriano; Tomasi, Cristina; Scannapieco, Gianluigi; Ascani, Alessandra; Villalta, Sabina; Frulla, Michela; Mosena, Laura; Girolami, Antonio; Vaccarino, Antonella; Alatri, Adriano; Palareti, Gualtiero; Marchesi, Mario // New England Journal of Medicine;7/19/2001, Vol. 345 Issue 3, p165 

    Background: In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. Whether this benefit persists after anticoagulant therapy is discontinued is...

  • Long term survival with a metallic mitral valve prosthesis on no anticoagulation or antiplatelet therapy. A case presentation. Perez-Zaldivar, Jose Ignacio; Orjiako, Livinus Obiora; Tutunovic, S. // Internet Journal of Cardiology;2010, Vol. 9 Issue 1, p1 

    Adequate anticoagulation is extremely important in patients with cardiac valve prosthesis because of the permanent risk of embolism or thrombosis of the valve. We present a curios case of a patient that never took any kind of anticoagulant for ten years after a mitral valve prosthesis, St Jude...

  • TREATMENT OF CHRONIC THROMBOEMBOLISM WITH ARVIN, ORAL FIBRINOLYTICS AND STANDARD ANTICOAGULANTS. Kounis, Nicholas G.; Evans, W. Howel // Vascular Surgery;Mar/Apr1977, Vol. 11 Issue 2, p68 

    In five patients suffering from recurrent deep venous thrombosis and pulmonary embolism, a therapeutic combination was applied including Arvin, Fearnley's regime and standard anticoagulants. In two patients complete remission of the disease seemed to he achieved during the following two years....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics